CadenceCadence
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
Category

Oncology Updates

Approval BlogMedical CommunicationsOncology Updates

Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Blinatumomab for Patients with MRD-positive B-cell Precursor ALL

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Medical CommunicationsOncology Updates

Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy

By Zachary Moore | Medical Communications, Oncology Updates
Medical CommunicationsOncology Updates

Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer

By Zachary Moore | Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
« Previous
NextPrevious »
Third time on the Inc. 5000, Ranking No. 3160 Learn More

Terms of Use | Privacy Policy

TRUSTe
"We use cookies to give you the best possible experience on our website. To learn more about cookies and how we use them please see our cookie policy here. See more information on changing cookie preferences here. Please be aware the site may not function properly without cookies. [ ] I consent.”
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok